Exact Sciences is partnering with two renowned healthcare organizations at the forefront of cancer research, the Broad Institute of MIT and Harvard along with Baylor Scott & White, the company announced recently.

According to a release, the agreement with Broad Institute of MIT and Harvard will provide an exclusive license to next-generation technology for ultra-sensitive detection of molecular residual disease and ongoing research. Meanwhile, the collaboration with Baylor Scott & White will lead to the creation of the Texas Multicancer Early Detection Registry program.

“These collaborations mark a significant milestone in Exact Sciences’ pursuit to eradicate cancer,” Exact Sciences Chief Science Officer Jorge Garces said in a statement. “Our combined efforts will unlock new insights into the complexities of cancer. We hope to enable preventative measures and treatments that address the unique needs of each patient to maximize their chances of achieving positive outcomes.”

The agreements will last five and three years, respectively.